Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNOC031: Protocol for Embryonal Tumor With Multilayered Rosettes (ETMR)
NCT06861244Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Mar 2025
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temozolomide in embryonal tumor with multilayered rosettes (ETMR) (4 cohorts), sponsored by University of California, San Francisco. Primary endpoint: Progression-Free Survival at 6 months. Started Mar 2025; status: recruiting.
02
Drugs
temozolomide
03
Conditions
embryonal tumor with multilayered rosettes (ETMR)
Beyond the preview
Go deeper on NCT06861244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861244.